Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07715409

Effect of Betadine Vaginal Cleansing Before Cesarean Section to Reduce Postoperative Infectious Morbidity

This randomized controlled trial aims to evaluate the efficacy of preoperative vaginal cleansing with 5% povidone-iodine in reducing postoperative infectious morbidity among women undergoing cesarean section. The primary outcomes include wound-related complications, while secondary outcomes include postoperative fever, endometritis, wound infection, and white blood cell count.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cesarean Section Adnexal Diseases Endometritis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pelvic Inflammatory Disease Postoperative Complications Surgical Site Infection Surgical Wound Infection Urogenital Diseases Uterine Diseases Wound Infection

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Al-Azhar University Hospital, Damietta

Damietta, Damietta Governorate, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women undergoing elective or emergency cesarean section. Received prophylactic antibiotics before surgery

Exclusion criteria

  • Active infection No prophylactic antibiotics Chorioamnionitis Placenta previa with antepartum hemorrhage

Treatment and study plan

Povidone-iodine 5% solution

Drug

Vaginal cleansing with 5% povidone-iodine for 30 seconds before cesarean section.

Primary outcomes

  1. Incidence of postoperative wound-related complications Time Frame: Within 8 weeks after cesarean section

    Time frame: 8 weeks

  2. Incidence of postoperative wound-related complications

    Time frame: Within 8 weeks after cesarean section

Secondary outcomes

  1. Postoperative fever (within 8 weeks) Postoperative WBC count (24 hours) Endometritis (within 8 weeks) Combined wound complications and endometritis

    Time frame: 8 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

mohamed mousa Al-Azhar University Hospital, Damietta

CONTACT

[email protected]

2001021267963 ext. 2001092646269

mohamed mousa mohamed

CONTACT

Sponsors and collaborators

Lead sponsor

Mohamed Mousa Mohamed Mousa

Other

Registry information

Important dates

Study start
2027
Primary completion
2027
Study completion
2027
First posted
Jul 20, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.